FGFR2 rearrangement
|
Cholangiocarcinoma
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
infigratinib Sensitive: A1 - Approval
|
infigratinib Sensitive: A1 - Approval
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
infigratinib Sensitive: A1 - Approval
|
infigratinib Sensitive: A1 - Approval
|
IDH1 mutation
|
Cholangiocarcinoma
|
IDH1 mutation
|
Cholangiocarcinoma
|
ivosidenib Sensitive: A1 - Approval
|
ivosidenib Sensitive: A1 - Approval
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
pemigatinib Sensitive: A1 - Approval
|
pemigatinib Sensitive: A1 - Approval
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
pemigatinib Sensitive: A1 - Approval
|
pemigatinib Sensitive: A1 - Approval
|
No biomarker
|
Cholangiocarcinoma
|
No biomarker
|
Cholangiocarcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Cholangiocarcinoma
|
No biomarker
|
Cholangiocarcinoma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Cholangiocarcinoma
|
No biomarker
|
Cholangiocarcinoma
|
infigratinib Sensitive: B - Late Trials
|
infigratinib Sensitive: B - Late Trials
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
TAS 120 Sensitive: B - Late Trials
|
TAS 120 Sensitive: B - Late Trials
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
TAS 120 Sensitive: B - Late Trials
|
TAS 120 Sensitive: B - Late Trials
|
HER-2 expression
|
Cholangiocarcinoma
|
HER-2 expression
|
Cholangiocarcinoma
|
trastuzumab + lapatinib Sensitive: B - Late Trials
|
trastuzumab + lapatinib Sensitive: B - Late Trials
|
No biomarker
|
Cholangiocarcinoma
|
No biomarker
|
Cholangiocarcinoma
|
TT-00420 Sensitive: B - Late Trials
|
TT-00420 Sensitive: B - Late Trials
|
RET fusion
|
Cholangiocarcinoma
|
RET fusion
|
Cholangiocarcinoma
|
pralsetinib Sensitive: C1 - Off-label
|
pralsetinib Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Cholangiocarcinoma
|
BRCA2 mutation
|
Cholangiocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Cholangiocarcinoma
|
BRCA1 mutation
|
Cholangiocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
FGFR3 mutation
|
Cholangiocarcinoma
|
FGFR3 mutation
|
Cholangiocarcinoma
|
erdafitinib Sensitive: C1 - Off-label
|
erdafitinib Sensitive: C1 - Off-label
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
erdafitinib Sensitive: C1 - Off-label
|
erdafitinib Sensitive: C1 - Off-label
|
NTRK3 fusion
|
Cholangiocarcinoma
|
NTRK3 fusion
|
Cholangiocarcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Cholangiocarcinoma
|
NTRK2 fusion
|
Cholangiocarcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK1 fusion
|
Cholangiocarcinoma
|
NTRK1 fusion
|
Cholangiocarcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
BRAF V600
|
Cholangiocarcinoma
|
BRAF V600
|
Cholangiocarcinoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Cholangiocarcinoma
|
MSI-H/dMMR
|
Cholangiocarcinoma
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
BRAF V600E
|
Cholangiocarcinoma
|
BRAF V600E
|
Cholangiocarcinoma
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Cholangiocarcinoma
|
NTRK2 fusion
|
Cholangiocarcinoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
NTRK3 fusion
|
Cholangiocarcinoma
|
NTRK3 fusion
|
Cholangiocarcinoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
NTRK1 fusion
|
Cholangiocarcinoma
|
NTRK1 fusion
|
Cholangiocarcinoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Cholangiocarcinoma
|
HER-2 overexpression
|
Cholangiocarcinoma
|
lapatinib Sensitive: C1 - Off-label
|
lapatinib Sensitive: C1 - Off-label
|
BRAF V600E
|
Cholangiocarcinoma
|
BRAF V600E
|
Cholangiocarcinoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
FGFR2 translocation
|
Cholangiocarcinoma
|
FGFR2 translocation
|
Cholangiocarcinoma
|
pemigatinib Sensitive: C2 – Inclusion Criteria
|
pemigatinib Sensitive: C2 – Inclusion Criteria
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
FGFR2 amplification
|
Cholangiocarcinoma
|
FGFR2 amplification
|
Cholangiocarcinoma
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
IDH2 mutation
|
Cholangiocarcinoma
|
IDH2 mutation
|
Cholangiocarcinoma
|
dasatinib Sensitive: C2 – Inclusion Criteria
|
dasatinib Sensitive: C2 – Inclusion Criteria
|
IDH1 R132C
|
Cholangiocarcinoma
|
IDH1 R132C
|
Cholangiocarcinoma
|
ivosidenib Sensitive: C2 – Inclusion Criteria
|
ivosidenib Sensitive: C2 – Inclusion Criteria
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
TT-00420 Sensitive: C2 – Inclusion Criteria
|
TT-00420 Sensitive: C2 – Inclusion Criteria
|
NRG1 fusion
|
Cholangiocarcinoma
|
NRG1 fusion
|
Cholangiocarcinoma
|
MCLA-128 Sensitive: C2 – Inclusion Criteria
|
MCLA-128 Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Cholangiocarcinoma
|
HER-2 amplification
|
Cholangiocarcinoma
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
DDR
|
Cholangiocarcinoma
|
DDR
|
Cholangiocarcinoma
|
lenvatinib + toripalimab Sensitive: C3 – Early Trials
|
lenvatinib + toripalimab Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Cholangiocarcinoma
|
PD-L1 expression
|
Cholangiocarcinoma
|
lenvatinib + toripalimab Sensitive: C3 – Early Trials
|
lenvatinib + toripalimab Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Cholangiocarcinoma
|
ARID1A mutation
|
Cholangiocarcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
FGFR1 fusion
|
Cholangiocarcinoma
|
FGFR1 fusion
|
Cholangiocarcinoma
|
erdafitinib Sensitive: C3 – Early Trials
|
erdafitinib Sensitive: C3 – Early Trials
|
KRAS G12C
|
Cholangiocarcinoma
|
KRAS G12C
|
Cholangiocarcinoma
|
MRTX849 Sensitive: C3 – Early Trials
|
MRTX849 Sensitive: C3 – Early Trials
|
POLE mutation
|
Cholangiocarcinoma
|
POLE mutation
|
Cholangiocarcinoma
|
PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
Cholangiocarcinoma
|
POLE mutation
|
Cholangiocarcinoma
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
Cholangiocarcinoma
|
POLE mutation
|
Cholangiocarcinoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
MET-H
|
Cholangiocarcinoma
|
MET-H
|
Cholangiocarcinoma
|
cabozantinib tablet Sensitive: C3 – Early Trials
|
cabozantinib tablet Sensitive: C3 – Early Trials
|
TIMP1-L
|
Cholangiocarcinoma
|
TIMP1-L
|
Cholangiocarcinoma
|
cabozantinib tablet Sensitive: C3 – Early Trials
|
cabozantinib tablet Sensitive: C3 – Early Trials
|
FGFR2-BICC1 fusion
|
Cholangiocarcinoma
|
FGFR2-BICC1 fusion
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
FGFR2-SORBS1 fusion
|
Cholangiocarcinoma
|
FGFR2-SORBS1 fusion
|
Cholangiocarcinoma
|
TAS 120 Resistant: C3 – Early Trials
|
TAS 120 Resistant: C3 – Early Trials
|
FGFR3 fusion
|
Cholangiocarcinoma
|
FGFR3 fusion
|
Cholangiocarcinoma
|
Debio 1347 Sensitive: C3 – Early Trials
|
Debio 1347 Sensitive: C3 – Early Trials
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
Debio 1347 Sensitive: C3 – Early Trials
|
Debio 1347 Sensitive: C3 – Early Trials
|
FGFR1 fusion
|
Cholangiocarcinoma
|
FGFR1 fusion
|
Cholangiocarcinoma
|
Debio 1347 Sensitive: C3 – Early Trials
|
Debio 1347 Sensitive: C3 – Early Trials
|
TP53 mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
TP53 mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
TP53 mutation + FGFR2 fusion
|
Cholangiocarcinoma
|
TP53 mutation + FGFR2 fusion
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
PBRM1 mutation + FGFR2 fusion
|
Cholangiocarcinoma
|
PBRM1 mutation + FGFR2 fusion
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
PIK3CA mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
PIK3CA mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
PIK3CB mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
PIK3CB mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
PIK3R1 mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
PIK3R1 mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
BAP1 mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
BAP1 mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
BAP1 mutation + FGFR2 fusion
|
Cholangiocarcinoma
|
BAP1 mutation + FGFR2 fusion
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
IDH1 mutation + FGFR2 fusion
|
Cholangiocarcinoma
|
IDH1 mutation + FGFR2 fusion
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
IDH1 mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
IDH1 mutation + FGFR2 rearrangement
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
FGFR2-BICC1 fusion
|
Cholangiocarcinoma
|
FGFR2-BICC1 fusion
|
Cholangiocarcinoma
|
infigratinib + PD 0173074 Sensitive: C3 – Early Trials
|
infigratinib + PD 0173074 Sensitive: C3 – Early Trials
|
FGFR2-AHCYL1 fusion
|
Cholangiocarcinoma
|
FGFR2-AHCYL1 fusion
|
Cholangiocarcinoma
|
infigratinib + PD 0173074 Sensitive: C3 – Early Trials
|
infigratinib + PD 0173074 Sensitive: C3 – Early Trials
|
FGFR2 Y376C
|
Cholangiocarcinoma
|
FGFR2 Y376C
|
Cholangiocarcinoma
|
ABSK091 Sensitive: C3 – Early Trials
|
ABSK091 Sensitive: C3 – Early Trials
|
BAP1 mutation
|
Cholangiocarcinoma
|
BAP1 mutation
|
Cholangiocarcinoma
|
cisplatin + gemcitabine Resistant: C3 – Early Trials
|
cisplatin + gemcitabine Resistant: C3 – Early Trials
|
MALT1 expression
|
Cholangiocarcinoma
|
MALT1 expression
|
Cholangiocarcinoma
|
regorafenib Sensitive: C3 – Early Trials
|
regorafenib Sensitive: C3 – Early Trials
|
EFNB2 positive
|
Cholangiocarcinoma
|
EFNB2 positive
|
Cholangiocarcinoma
|
sEphB4-HSA Sensitive: C3 – Early Trials
|
sEphB4-HSA Sensitive: C3 – Early Trials
|
EFNB2 negative
|
Cholangiocarcinoma
|
EFNB2 negative
|
Cholangiocarcinoma
|
sEphB4-HSA Sensitive: C3 – Early Trials
|
sEphB4-HSA Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Cholangiocarcinoma
|
HER-2 amplification
|
Cholangiocarcinoma
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
FGFR2 C382R
|
Cholangiocarcinoma
|
FGFR2 C382R
|
Cholangiocarcinoma
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
DCK positive
|
Cholangiocarcinoma
|
DCK positive
|
Cholangiocarcinoma
|
gemcitabine Sensitive: C3 – Early Trials
|
gemcitabine Sensitive: C3 – Early Trials
|
FGFR2-KIAA1217 fusion
|
Cholangiocarcinoma
|
FGFR2-KIAA1217 fusion
|
Cholangiocarcinoma
|
ARQ 087 Sensitive: C3 – Early Trials
|
ARQ 087 Sensitive: C3 – Early Trials
|
FGFR2-KIAA1217 fusion
|
Cholangiocarcinoma
|
FGFR2-KIAA1217 fusion
|
Cholangiocarcinoma
|
Debio 1347 Sensitive: C3 – Early Trials
|
Debio 1347 Sensitive: C3 – Early Trials
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 inhibitor Resistant: C3 – Early Trials
|
FGFR2 inhibitor Resistant: C3 – Early Trials
|
LMNA-NTRK1 fusion + NTRK1 G595R
|
Cholangiocarcinoma
|
LMNA-NTRK1 fusion + NTRK1 G595R
|
Cholangiocarcinoma
|
TPX-0005 Sensitive: C3 – Early Trials
|
TPX-0005 Sensitive: C3 – Early Trials
|
MSI-H/dMMR + TMB-L
|
Cholangiocarcinoma
|
MSI-H/dMMR + TMB-L
|
Cholangiocarcinoma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PTEN mutation + MSI-H/dMMR
|
Cholangiocarcinoma
|
PTEN mutation + MSI-H/dMMR
|
Cholangiocarcinoma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
FGFR2 F276C
|
Cholangiocarcinoma
|
FGFR2 F276C
|
Cholangiocarcinoma
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
FGFR2 translocation
|
Cholangiocarcinoma
|
FGFR2 translocation
|
Cholangiocarcinoma
|
ICP-192 Sensitive: C3 – Early Trials
|
ICP-192 Sensitive: C3 – Early Trials
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
ICP-192 Sensitive: C3 – Early Trials
|
ICP-192 Sensitive: C3 – Early Trials
|
IDH1 mutation
|
Cholangiocarcinoma
|
IDH1 mutation
|
Cholangiocarcinoma
|
metformin Sensitive: C3 – Early Trials
|
metformin Sensitive: C3 – Early Trials
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
Debio 1347 Sensitive: C3 – Early Trials
|
Debio 1347 Sensitive: C3 – Early Trials
|
FGFR mutation
|
Cholangiocarcinoma
|
FGFR mutation
|
Cholangiocarcinoma
|
ponatinib Sensitive: C3 – Early Trials
|
ponatinib Sensitive: C3 – Early Trials
|
FGFR mutation
|
Cholangiocarcinoma
|
FGFR mutation
|
Cholangiocarcinoma
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
FGFR fusion
|
Cholangiocarcinoma
|
FGFR fusion
|
Cholangiocarcinoma
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
IFNG-L
|
Cholangiocarcinoma
|
IFNG-L
|
Cholangiocarcinoma
|
bexmarilimab Sensitive: C3 – Early Trials
|
bexmarilimab Sensitive: C3 – Early Trials
|
TNFA-L
|
Cholangiocarcinoma
|
TNFA-L
|
Cholangiocarcinoma
|
bexmarilimab Sensitive: C3 – Early Trials
|
bexmarilimab Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Cholangiocarcinoma
|
HER-2 mutation
|
Cholangiocarcinoma
|
trastuzumab Resistant: C4 – Case Studies
|
trastuzumab Resistant: C4 – Case Studies
|